First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer:A United States-based cost-effectiveness analysis

Daniel A. Goldstein, Qiushi Chen, Turgay Ayer, David H. Howard, Joseph Lipscomb, Bassel F. El-Rayes, Christopher R. Flowers

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer:A United States-based cost-effectiveness analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences